Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease

REFERENCES

• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–380.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shahram F, Chams-Davatchi C, et al. Behcet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis. 2010;13(4):367–373.
   PubMed Web of Science ®Google Scholar
• el Belhadji M, Hamdani M, Laouissi N, et al. [Ophthalmological involvement in Behcet disease. Apropos of 520 cases]. J Fr Ophtalmol. 1997;20(8):592–598.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D, et al. Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis. 2009;68(10):1528–1534.
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum. 2004;33(5):320–335.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol. 2008;146(6):837–844.e1.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692–1695.
   PubMed Web of Science ®Google Scholar
• Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35(5):896–903.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kotter I, Gunaydin I, et al. [Ocular involvement in Behcet’s disease: first 5-year-results for visual development after treatment with interferon alfa-2a]. Ophthalmologe. 2004;101(2):129–134.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467–471.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol. 1998;134(8):1010–1016.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129(3):288–294.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kotter I, Wallace GR, et al. Behcet’s disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27(1):111–136.
   PubMed Web of Science ®Google Scholar
• Pfeffer LM, Kim JG, Pfeffer SR, et al. Role of nuclear factor-kappaB in the antiviral action of interferon and interferon-regulated gene expression. J Biol Chem. 2004;279(30):31304–31311.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprine for the uveitis of Behcet’s disease: an open study. Isr Med Assoc J. 2002;4(11 Suppl) :928–930.
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet’s uveitis refractory to conventional treatments. Ophthalmology. 2010;117(7):1430–1435.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Mohle A, et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum. 2010;62(9):2796–2805.
   PubMed Web of Science ®Google Scholar
• Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423–431.
   PubMed Web of Science ®Google Scholar
• Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behcet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61–70.
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161–1164.
   PubMed Web of Science ®Google Scholar
• Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet’s uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474–484.
   PubMed Web of Science ®Google Scholar
• Adan A, Hernandez V, Ortiz S, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behcet’s disease after withdrawal of infusions. Int Ophthalmol. 2010;30(5):577–581.
   PubMedGoogle Scholar
• Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130(5):592–598.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–796.e3.
   PubMed Web of Science ®Google Scholar
• Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behcet’s disease. Br J Ophthalmol. 2000;84(12):1437–1438.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol. 2008;146(6):845–850.e1.
   PubMed Web of Science ®Google Scholar
• Pay S, Simsek I, Erdem H, et al. Immunopathogenesis of Behcet’s disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int. 2007;27(5):417–424.
   PubMed Web of Science ®Google Scholar
• Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev. 2010;9(4):241–245.
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun M, Wechsler B, Geri G, et al. New insights into the pathogenesis of Behcet’s disease. Autoimmun Rev. 2012;11(10):687–698.
   PubMed Web of Science ®Google Scholar
• Mahr A, Maldini C. [Epidemiology of Behcet’s disease]. Rev Med Interne. 2014;35(2):81–89.
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144(1):55–61.
   PubMed Web of Science ®Google Scholar
• Raza A, Mittal S, Sood GK. Interferon-associated retinopathy during the treatment of chronic hepatitis C: a systematic review. J Viral Hepat. 2013;20(9):593–599.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Sellam J, Batteux F, et al. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol. 2004;22(6):756–758.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–912.
   PubMedGoogle Scholar